FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387405448> ?p ?o ?g. }

• W4387405448 abstract "Abstract Disclosure: R.J. Kildemoes: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. Y. Kamal Lyauk: Employee; Self; Novo Nordisk. J.C. Blair: Speaker; Self; Novo Nordisk, Pfizer, Inc., Ipsen. Other; Self; Novo Nordisk. B.S. Miller: Consulting Fee; Self; Novo Nordisk, Abbvie, Endo Pharmaceuticals, Ascendis Pharma, Bristol-Myers Squibb, Pfizer, Inc., EMD Serono, BioMarin Pharmaceutical, Tolmar. Research Investigator; Self; Alexion Pharmaceuticals, Inc., Abbvie, Aeterna Zentaris, Amicus, Lumos Pharma, Novo Nordisk, Lysogene, OPKO Health, Pfizer, Inc., Prevail Therapeutics, Sangamo Therapeutics. J. Mori: None. M. Højby Rasmussen: Employee; Self; Novo Nordisk. Stock Owner; Self; Novo Nordisk. P.F. Backeljauw: Consulting Fee; Self; Novo Nordisk, Novartis Pharmaceuticals, Ascendis Pharma, BioMarin Pharmaceutical, Tolmar Pharmaceuticals, Cavalry Biosciences, Ipsen. Research Investigator; Self; Novo Nordisk, Novartis Pharmaceuticals, Ipsen. Growth hormone (GH) replacement therapy improves overall health and adult height in children with GH deficiency (GHD). GH stimulates insulin-like growth factor-I (IGF-I) release, the biomarker commonly used for guiding GH dose adjustments to ensure optimal long-term safety and efficacy. This study aims to provide model-based insights into the dose-IGF-I responses of once-weekly somapacitan, a novel long-acting GH, compared to daily GH in pediatric patients with GHD. Pharmacokinetic/pharmacodynamic (PK/PD) modeling was used to characterize somapacitan dose-IGF-I response and to predict the response to change of dosing day and missed dosing of somapacitan. Analyses included dosing information and 1473 PK samples from 210 GHD patients treated with somapacitan across three trials: phase 1 (NCT01973244), phase 2 (NCT02616562; REAL3), and phase 3 (NCT03811535; REAL4), as well as 1381 IGF-I samples from 186 GHD patients treated with somapacitan from REAL3 and REAL4. A clear dose-response relationship was observed with increasing somapacitan exposure and increasing change from baseline IGF-I SDS. A linear model permitted the development of a tool to calculate the estimated average weekly IGF-I exposure from a single IGF-I sample obtained at any time within the somapacitan dosing interval at steady state. In practice, the use of this tool will require knowledge of the timing of the somapacitan injection relative to the timing of the IGF-I sample collection. IGF-I SDS simulations support flexible dosing day changes while maintaining a minimum of 4 days between doses. In this study, we present a practical guide that may inform clinicians about the expected weekly average IGF-I concentration in somapacitan-treated pediatric patients with GHD from a single sample taken on any chosen day during the weekly dosing interval. The ability to determine weekly average IGF-I enhances our understanding of somapacitan dosing and should support physicians in monitoring long-term safety and efficacy of this therapy. Furthermore, we provide insights on flexibility to change of dosing day and missed dosing of somapacitan. Presentation: Thursday, June 15, 2023" @default.
• W4387405448 created "2023-10-07" @default.
• W4387405448 creator A5001615647 @default.
• W4387405448 creator A5012791662 @default.
• W4387405448 creator A5044830255 @default.
• W4387405448 creator A5054090129 @default.
• W4387405448 creator A5055735580 @default.
• W4387405448 creator A5061113157 @default.
• W4387405448 creator A5091887291 @default.
• W4387405448 date "2023-10-01" @default.
• W4387405448 modified "2023-10-08" @default.
• W4387405448 title "THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency" @default.
• W4387405448 doi "https://doi.org/10.1210/jendso/bvad114.1425" @default.
• W4387405448 hasPublicationYear "2023" @default.
• W4387405448 type Work @default.
• W4387405448 citedByCount "0" @default.
• W4387405448 crossrefType "journal-article" @default.
• W4387405448 hasAuthorship W4387405448A5001615647 @default.
• W4387405448 hasAuthorship W4387405448A5012791662 @default.
• W4387405448 hasAuthorship W4387405448A5044830255 @default.
• W4387405448 hasAuthorship W4387405448A5054090129 @default.
• W4387405448 hasAuthorship W4387405448A5055735580 @default.
• W4387405448 hasAuthorship W4387405448A5061113157 @default.
• W4387405448 hasAuthorship W4387405448A5091887291 @default.
• W4387405448 hasBestOaLocation W43874054481 @default.
• W4387405448 hasConcept C10138342 @default.
• W4387405448 hasConcept C126322002 @default.
• W4387405448 hasConcept C162324750 @default.
• W4387405448 hasConcept C187212893 @default.
• W4387405448 hasConcept C2777288759 @default.
• W4387405448 hasConcept C2984496839 @default.
• W4387405448 hasConcept C3017619653 @default.
• W4387405448 hasConcept C71315377 @default.
• W4387405448 hasConcept C71924100 @default.
• W4387405448 hasConceptScore W4387405448C10138342 @default.
• W4387405448 hasConceptScore W4387405448C126322002 @default.
• W4387405448 hasConceptScore W4387405448C162324750 @default.
• W4387405448 hasConceptScore W4387405448C187212893 @default.
• W4387405448 hasConceptScore W4387405448C2777288759 @default.
• W4387405448 hasConceptScore W4387405448C2984496839 @default.
• W4387405448 hasConceptScore W4387405448C3017619653 @default.
• W4387405448 hasConceptScore W4387405448C71315377 @default.
• W4387405448 hasConceptScore W4387405448C71924100 @default.
• W4387405448 hasIssue "Supplement_1" @default.
• W4387405448 hasLocation W43874054481 @default.
• W4387405448 hasOpenAccess W4387405448 @default.
• W4387405448 hasPrimaryLocation W43874054481 @default.
• W4387405448 hasRelatedWork W1971885716 @default.
• W4387405448 hasRelatedWork W1992426253 @default.
• W4387405448 hasRelatedWork W2151922639 @default.
• W4387405448 hasRelatedWork W2159406923 @default.
• W4387405448 hasRelatedWork W2911677179 @default.
• W4387405448 hasRelatedWork W2915644342 @default.
• W4387405448 hasRelatedWork W3034286462 @default.
• W4387405448 hasRelatedWork W3166797618 @default.
• W4387405448 hasRelatedWork W4210913627 @default.
• W4387405448 hasRelatedWork W4288738052 @default.
• W4387405448 hasVolume "7" @default.
• W4387405448 isParatext "false" @default.
• W4387405448 isRetracted "false" @default.
• W4387405448 workType "article" @default.